Advances in technology are accelerating the development and manufacture of subunit vaccines.

Subunit Vaccines and the Fight Against COVID-19

Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.

Meeting the Demand for Lipid Excipients

Container and equipment innovations expand applications.

Innovations Meet Growing Demand for Prefilled Syringes

Topic

Articles

Meissa Vaccines’s MV-014-212, an intranasal recombinant live attenuated COVID-19 vaccine, induced mucosal and systemic antibodies against SARS-CoV-2 and two variants of concern.

Meissa’s Intranasal COVID-19 Vaccine Yields Promising Preclinical Data

The EMA’s CHMP has adopted a positive opinion recommending marketing authorization for Moderna’s COVID-19 vaccine (Spikevax) to include adolescents 12 years of age and older.

EMA’s CHMP Adopts Positive Opinion for Moderna COVID-19 Vaccine Use in Adolescents 

Pfizer Inc. and BioNTech SE announced the signing of a letter of intent with The Biovac Institute Ltd to manufacture the Pfizer-BioNTech COVID-19 vaccine for distribution within the African Union.

Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa

ImmunityBio will proceed with a Phase I/II/III trial in South Africa of their dual-antigen T-cell vaccine as a boost in participants who were previously vaccinated against COVID-19.

SAHPRA Authorizes ImmunityBio to Proceed with Trial of T-Cell Vaccine as Booster Against COVID-19

After a review of three cases, EMA's PRAC has advised against the use of Janssen’s COVID-19 vaccine in people who have a history of capillary leak syndrome.

EMA Advises Against Using Janssen’s COVID-19 Vaccine in People with Capillary Leak Syndrome

EMA's PRAC has found a possible link to very rare cases of myocarditis and pericarditis after vaccination with Comirnaty and Spikevax COVID-19 vaccines.

PRAC Finds Link to Very Rare Cases of Myocarditis and Pericarditis with Comirnaty and Spikevax

Moderna announces supply agreement with the Argentina government for 20 million doses of Moderna’s COVID-19 vaccine.

Moderna to Deliver 20 Million Doses of COVID-19 Vaccine to Argentina

The IND for Tevogen Bio's TVGN-489, an allogeneic COVID-19-specific cytotoxic T lymphocyte, received rapid clearance from FDA.

FDA Clears Tevogen Bio’s IND Application for CTL COVID-19 Treatment 

The approved changes to the API manufacturing plant in Leiden, the Netherlands will enable an increase in API capacity.

EMA Approves Scale-Up Process for Janssen COVID-19 Vaccine

 Washington Editor, jillwechsler7@gmail.com.

The rise of COVID variants has made public health officials anxious to expand immunity more widely and quickly in areas with low vaccination rates, and experts hope that full approval of existing and new vaccines will increase public confidence in their value.  

COVID-19 Update

Subunit Vaccines and the Fight Against COVID-19

Meeting the Demand for Lipid Excipients

Innovations Meet Growing Demand for Prefilled Syringes